COMMUNIQUÉS West-GlobeNewswire

Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging
15/09/2024
Prostate-specific membrane antigen (PSMA) is a leading target for next-generation prostate cancer therapies, with one FDA-approved medicine and 30 medicines in development Quantitative PSMA-PET imaging is required to [...]
23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
15/09/2024
23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit in clear-cell renal-cell carcinoma, with one confirmed partial response Higher tumor expression of CD200 and human genetics correlated with [...]
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
15/09/2024
23ME-01473 inhibited tumor growth in a patient-derived xenograft mouse model of non-small cell lung cancer Elevated levels of soluble and tumor-bound ULBP6 confirmed in squamous cell carcinomas and a subset of [...]
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
15/09/2024
Encouraging antitumor activity demonstrated with vobra duo as measured by 6-month landmark rPFS rate and ORR Patients remained on vobra duo through a median of 6 doses (ranging up to 12), representing an extension of [...]
New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer
15/09/2024
Investigational TAR-200 monotherapy demonstrates high complete response rate without the need for reinduction or additive therapy in patients who are Bacillus Calmette-Guérin (BCG)-unresponsive 1 BEERSE, BELGIUM , Sept [...]
RYBREVANT®▼ (amivantamab) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer
14/09/2024
Median duration of response reaches 7.4 months with combination treatment in patients with aggressive form of disease 1 New results show potential of amivantamab beyond lung cancer 1 BEERSE, BELGIUM, Sept. 14, 2024 ( [...]
Medigene Presents Progress on KRAS Library and UniTope & TraCR Technology at ESMO 2024
14/09/2024
Planegg/Martinsried, September 14, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies [...]
KFSHRC Revolutionizes Patient Care with Pioneering Experience Ambassadors Program
14/09/2024
RIYADH, Saudi Arabia, Sept. 14, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) is redefining patient engagement and care through its pioneering Experience Ambassadors Program. [...]
Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024
14/09/2024
Updated data show consistent objective response rate of 40% and manageable safety profile in patients with non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations treated with [...]
Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024
14/09/2024
Treatment data were analyzed from 3,276 cases of patients with newly diagnosed EGFR mutant NSCLC from Guardant Health Analyses of patients with non-classical EGFR mutations reveal that the majority receive frontline [...]
RYBREVANT®▼ (amivantamab) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer
14/09/2024
Post-progression outcomes showed significant and sustained improvement for amivantamab plus chemotherapy versus chemotherapy alone 1 BEERSE, BELGIUM , Sept. 14, 2024 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a [...]
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
14/09/2024
- 4.3 mg/kg of luveltamab tazevibulin (luvelta) in combination with standard dose of bevacizumab (15 mg/kg) every 3 weeks resulted in a 56% objective response rate in patients with late-stage ovarian cancer and was [...]
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
14/09/2024
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer Brenetafusp is clinically active as monotherapy and in combination with chemotherapy in heavily pre- [...]
Avacta Reports Updated Phase 1 Clinical Data of AVA6000 at the European Society for Medical Oncology (ESMO) Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors
14/09/2024
This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended (" [...]
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer
14/09/2024
-- Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the Head and Neck Cohort -- -- No New Safety Signals or Added Systemic [...]
iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
14/09/2024
- Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose - >30% cORR difference between belrestotug + [...]
Company Statement on FDA Advisory Committee Meeting
14/09/2024
MORRISTOWN, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- The Gastrointestinal Drugs Advisory Committee (GIDAC) of the U.S. Food and Drug Administration (FDA) met today to discuss Intercept’s supplemental New Drug [...]
Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.
14/09/2024
MARKHAM, Ontario, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Dr. Pardeep Nijhawan (“ Dr. Nijhawan ”) announces that as a result of grants of restricted share units (“ RSUs ”) of Edesa Biotech, Inc. (“ Edesa ”), when combined [...]
Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq
13/09/2024
NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM) announced that on September 12, 2024, the Company received a staff determination letter (the “Determination Letter”) [...]

Pages